{'fraction_non_alphanumeric': 0.027750247770069375, 'fraction_numerical': 0.002973240832507433, 'mean_word_length': 5.234567901234568, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Usefulness of liposomal amphotericin B for the prophylaxis of fungal infection in solid organ transplant recipients].

Solid organ transplantation is the best alternative for the treatment of end-stage kidney, liver, heart, pancreas and lung failure. Fungal infections (the most frequent are Candida spp. and Aspergillus spp.) are associated with highest mortality in solid organ transplantation. The systemic use of liposomal amphotericin B has only been studied in liver transplant recipients. The main conclusions that can be drawn from the five studies that have been published are: 1) for the prophylaxis to be effective against Aspergillus spp., a dose of 5 mg/kg/day must be used; 2) its use must be reserved for situations with the highest risk for invasive fungal infections: retransplantation, the need for resurgery and, mainly, for those patients needing haemodialysis. Preliminary studies for the prophylactic use of nebulized liposomal amphotericin B in lung transplant receptors are promising.